laboratory crp of amer hldgs (LH) Key Developments
Epic Sciences Expands Partnership with Laboratory Corp. of America Holdings to Provide Circulating Tumor Cell Analysis, Support Oncology Clinical Trials in Asia
Jul 7 15
Epic Sciences (Epic) announced an agreement with Laboratory Corporation of America Holdings to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development (Covance). Covance will process patient samples in Singapore, and then send samples to Epic's clinical laboratory in San Diego, which has recently been licensed under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, for downstream detection and molecular characterization of CTCs. This agreement expands on a previous contract announced last year between Epic and LabCorp for European clinical trials.
Laboratory Corp. of America Holdings Presents at Piper Jaffray Heartland Summit, Jun-23-2015
Jun 19 15
Laboratory Corp. of America Holdings Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: David P. King, Chairman and Chief Executive Officer.
Laboratory Corp. of America Seeks Acquisitions
Jun 9 15
Laboratory Corp. of America Holdings (NYSE:LH) is seeking acquisitions. Dave King, Chairman and Chief Executive Officer, said, "We have an undrawn revolver, we have good accumulation of cash, we do intend to continue to do the tuck-in and fold-in acquisitions that we've historically done, even through the delevering process."
LabCorp Expands Access to LabCorp AccuDraw to Support Better Patient Care
Jun 4 15
Laboratory Corporation of America Holdings announced the expanded availability of its proprietary specimen collection and handling software, LabCorpAccuDraw. Combining on-screen visual cues with step-by-step tutorials, AccuDraw is an innovative tool designed to guide the health care professional who collects patient specimens throughout the specimen collection process. AccuDrawhelps to facilitate collection and appropriate stabilization of the correct specimen type and sample volume. This technology-enabled solution leads to fewer errors in specimen collection and processing, a reduced chance of delays in testing, and a lower likelihood of having a patient undergo a second visit to a health care professional for further specimen collection. AccuDraw has been used in LabCorp's patient service centers and by LabCorp’s phlebotomists located in client locations for over five years. AccuDrawhas previously only been, and will continue to be, available to LabCorp clients through the LabCorp Beacon application. AccuDraw provides a detailed set of specimen collection and handling instructions, allowing office staff to spend more time on patient care and less time confirming the specimen collection process and requirements. On-screen visual cues are combined with detailed collection instructions to help ensure specimen and collection accuracy in the physician office. For patients and the physician office, AccuDraw provides: Improved precision and accuracy – Visual cues are customized to the specific physician test order and linked to LabCorp’s current test requirements. High-quality specimens – the guided process and clear instructions helps to ensure the quality specimen is sent to the laboratory for testing. Time efficiencies – Reduce the amount of time spent speaking to the lab about specimen requirements or identifying specimens that were not properly submitted to the lab. Reduction in repeat draws – AccuDraw’s collection, handling, and shipping guidance significantly reduces the need for patient redraws and repeat visits.
Sysmex Corp. and Laboratory Corp. of America Holdings Announce a Strategic Collaboration for Blood-Based Molecular Testing Services and Products
Jun 1 15
Sysmex Corp. and Laboratory Corp. of America Holdings announced a strategic collaboration focused on the development of blood-based molecular diagnostic tests to advance precision medicine in oncology. The collaboration combines Sysmex Inostics’ strength in the development of innovative blood-based diagnostic solutions with LabCorp's unparalleled capabilities: global leadership in precision medicine through Covance Drug Development’s (Covance) extensive involvement in oncology clinical trials and a unique ability to commercialize clinically-relevant diagnostic tests through LabCorp Diagnostics as such applications are developed. The Sysmex OncoBEAM™ and Plasma Sequencing assays allow for molecular genetic analysis of cell-free tumor DNA from blood samples. These technologies, often referred to as liquid biopsies, provide non-invasive alternatives to biopsies under specific circumstances and are designed to determine the mutational status of a patient’s tumor. These highly-sensitive methods allow for the potential selection of appropriate therapeutic agents and, in some cases, may eliminate the need for further surgeries or biopsies. Moreover, blood-based diagnostic DNA tests can be performed when no tumor tissue is available and utilized to serially monitor tumor changes in patients over time or in response to therapeutic treatment. The OncoBEAM™ assays target a wide variety of clinically actionable genetic mutations in cancer and, along with sequencing-based evaluation of circulating tumor DNA through Plasma Sequencing, offer biopharmaceutical companies powerful tools for developing new therapeutic options. Under the terms of this collaboration, Sysmex Inostics will provide reagents and, when appropriate, services to enable Covance’s central laboratory to perform OncoBEAM™ and Plasma Sequencing testing services in its global locations to support oncology clinical trials. In addition, as clinical utility of these technologies is further characterized through ongoing clinical trials, the parties will evaluate opportunities to develop commercial applications for Sysmex’s technologies in clinical diagnostics.